<DOC>
	<DOCNO>NCT00442533</DOCNO>
	<brief_summary>The purpose study determine High-dose 111In-Pentetreotide know NeuroendoMedixÂ® , effective treatment Neuroendocrine Tumors .</brief_summary>
	<brief_title>Safety Efficacy Study In-111 Pentetreotide Treat Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patients must receive first line standard chemotherapy and/or radiation therapy neuroendocrine malignancy past failed therapy . Patients must evidence residual multifocal active tumor . All patient must sign informed consent indicate awareness investigational nature study involve . All patient must Karnofsky performance status least 60 . Patients must great 18 year age . Patients must measurable and/or followable disease base either clinical radiologic exam . Sensitivity Indium111 pentetreotide component absolute contraindication participation trial . An absolute contraindication pregnancy evidence clinical condition , positive pregnancy test ( BHCG pelvic ultrasound ) . If patient receive prior radionuclide therapy product , must document response therapy and/or residual active stable disease . Karnofsky performance status 50 less . Patients unable give inform consent . Patients 18 year age . There upper age discrimination . Patients pregnant potentially pregnant subject willing practice effective contraceptive technique study period . Patients renal insufficiency define calculated creatinine clearance ( base age , weight serum creatinine ) 39.9 ml/min less .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Carcinoid</keyword>
	<keyword>Islet Cell Cancer</keyword>
	<keyword>Paraganglioma</keyword>
	<keyword>Pheochromocytoma</keyword>
</DOC>